Cyclophosphamide
- Generic Name
- Cyclophosphamide
- Brand Names
- Procytox
- Drug Type
- Small Molecule
- Chemical Formula
- C7H15Cl2N2O2P
- CAS Number
- 50-18-0
- Unique Ingredient Identifier
- 6UXW23996M
- Background
Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.
- Indication
Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patients.
- Associated Conditions
- Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Acute monocytic leukemia, Adenocarcinoma of the Ovaries, Breast Cancer, Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia (CML), Hodgkins Disease (HD), Lung Cancer, Lupus, Lymphocytic Lymphomas, Lymphoma, Multiple Myeloma (MM), Multiple Sclerosis, Nephrotic syndrome with lesion of minimal change glomerulonephritis, Non-Hodgkin's Lymphoma (NHL), Retinoblastoma, Advanced Alibert-Bazin syndrome, Chronic Granulocytic Leukemias, Disseminated Neuroblastoma (NB), Histiocytic lymphoma, Mixed-cell type lymphoma
- Associated Therapies
- -
Pharmacologic Pretransplant Immunosuppression (PTIS) + Reduced Toxicity Conditioning (RTC) Allogeneic Stem Cell Transplantation in Inherited Hematologic Disorders
- Conditions
- Stem Cell Transplantation
- Interventions
- First Posted Date
- 2022-03-24
- Last Posted Date
- 2023-09-21
- Lead Sponsor
- M.D. Anderson Cancer Center
- Registration Number
- NCT05293509
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Mecapegfilgrastim With Chemotherapy for Peripheral Blood Stem Cell Mobilization in MM and Lymphoma
- Conditions
- Multiple MyelomaLymphoma
- Interventions
- First Posted Date
- 2022-03-24
- Last Posted Date
- 2022-12-02
- Lead Sponsor
- Qiu Lugui
- Target Recruit Count
- 120
- Registration Number
- NCT05294055
- Locations
- 🇨🇳
Anhui Provincial Hospital, Hefei, Anhui, China
🇨🇳Peking University Third Hospital, Beijing, Beijing, China
🇨🇳Henan Cancer Hospital, Zhengzhou, Henan, China
Post-Transplant Cyclophosphamide, Bortezomib and Abatacept for the Prevention of Graft-versus-Host-Disease (GvHD)
- Conditions
- Graft-versus-host Disease
- Interventions
- First Posted Date
- 2022-03-21
- Last Posted Date
- 2024-12-27
- Lead Sponsor
- Northwell Health
- Target Recruit Count
- 74
- Registration Number
- NCT05289167
- Locations
- 🇺🇸
Northwell Health, New Hyde Park, New York, United States
Adjuvant Albumin-bound Paclitaxel Versus Taxanes in Breast Cancer: a Real-world Study
- Conditions
- Breast Cancer
- Interventions
- Drug: doxorubicinDrug: epirubicinDrug: pirarubicinDrug: cyclophosphamideDrug: albumin-bound paclitaxelDrug: paclitaxelDrug: docetaxel
- First Posted Date
- 2022-03-18
- Last Posted Date
- 2022-03-31
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 500
- Registration Number
- NCT05287308
- Locations
- 🇨🇳
Cancer Hospital, ChineseAMS, Beijing, Beijing, China
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma
- Conditions
- Non-Hodgkin Lymphoma
- Interventions
- First Posted Date
- 2022-03-17
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Genmab
- Target Recruit Count
- 394
- Registration Number
- NCT05283720
- Locations
- 🇺🇸
Alliance for Multispecialty Research (AMR) - Kansas City /ID# 242144, Kansas City, Missouri, United States
🇺🇸Northwell Health - Monter Cancer Center /ID# 245435, Lake Success, New York, United States
🇺🇸Icahn School of Medicine at Mount Sinai /ID# 242123, New York, New York, United States
A Phase Ib Safety lead-in, Followed by Phase II Trial of ADG106 in Combination With Neoadjuvant Chemotherapy in HER2 Negative Breast Cancer
- Conditions
- HER2-negative Breast CancerAdvanced Solid Tumor
- Interventions
- First Posted Date
- 2022-03-11
- Last Posted Date
- 2024-05-17
- Lead Sponsor
- National University Hospital, Singapore
- Target Recruit Count
- 66
- Registration Number
- NCT05275777
- Locations
- 🇸🇬
National University Hospital, Singapore, Singapore
Loncastuximab Tesirine in Combination With DA-EPOCH-R in Patients With Previously Untreated Aggressive B-cell Lymphoid Malignancies
- Conditions
- B-cell LymphomaBurkitt Lymphoma
- Interventions
- Drug: EtoposideDrug: DoxorubicinDrug: CyclophosphamideDrug: RituximabDrug: VincristineDrug: PrednisoneDrug: Loncastuximab Tesirine 0.075 mg/kg by IVDrug: Loncastuximab tesirine 0.12 mg/kg by IVDrug: Loncastuximab tesirine 0.15 mg/kg by IV
- First Posted Date
- 2022-03-08
- Last Posted Date
- 2024-06-04
- Lead Sponsor
- Medical College of Wisconsin
- Target Recruit Count
- 33
- Registration Number
- NCT05270057
- Locations
- 🇺🇸
University of Texas Southwestern, Dallas, Texas, United States
🇺🇸University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, United States
🇺🇸Froedtert Hospital & the Medical College of Wisconsin, Milwaukee, Wisconsin, United States
Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors
- Conditions
- Clinical Stage III Gastric Cancer AJCC v8Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8Locally Advanced Gastric AdenocarcinomaLocally Advanced Gastroesophageal Junction AdenocarcinomaLocally Advanced Skin Squamous Cell CarcinomaLocally Advanced Triple-Negative Breast CarcinomaAnatomic Stage IV Breast Cancer AJCC v8Clinical Stage IVB Gastric Cancer AJCC v8Locally Advanced Renal Cell Carcinoma
- Interventions
- Drug: CyclophosphamideBiological: Neoantigen Peptide VaccineBiological: PembrolizumabBiological: Sargramostim
- First Posted Date
- 2022-03-08
- Last Posted Date
- 2024-06-12
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 36
- Registration Number
- NCT05269381
- Locations
- 🇺🇸
Mayo Clinic in Florida, Jacksonville, Florida, United States
A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2022-02-25
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Stichting European Myeloma Network
- Target Recruit Count
- 750
- Registration Number
- NCT05257083
- Locations
- 🇺🇸
University of Arkansas, Little Rock, Arkansas, United States
🇺🇸City of Hope, Duarte, California, United States
🇺🇸UC San Diego Health Moores Cancer Center, San Diego, California, United States
A Study of Daratumumab-Based Therapies in Participants With Amyloid Light Chain (AL) Amyloidosis
- Conditions
- Amyloidosis
- Interventions
- First Posted Date
- 2022-02-22
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 150
- Registration Number
- NCT05250973
- Locations
- 🇺🇸
West Penn Hospital, Pittsburgh, Pennsylvania, United States
🇺🇸University of Washington, Seattle, Washington, United States
🇬🇧University College Hospital, London, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.